Director Howard Berman Receives Equity Awards at Atea Pharmaceuticals

This Form 4 filing discloses equity awards granted to Howard Berman, a director of Atea Pharmaceuticals, Inc. On June 18, 2026, Berman received 26,700 restricted stock units (RSUs) and 37,700 stock options. The RSUs vest in a single installment on the earlier of the next annual stockholders meeting after June 18, 2026 or June 18, 2027, contingent on continued service. The stock options have an exercise price of $4.36 per share, vest in twelve monthly installments beginning June 18, 2026, and expire on June 17, 2036. Both awards were granted at $0 cost to the director. Following these transactions, Berman holds 26,700 RSUs and 37,700 stock options. The filing was signed by attorney-in-fact Andrea Corcoran on June 23, 2026.